Effect of Nursing Managers' Ethical Leadership on Clinical Nurse Empowerment, Performance, and Organizational Commitment. [PDF]
Kim J, Jeong SH, Kim HS, Lee MH.
europepmc +1 more source
Subjective Well-Being in Organizations: Effects of Internal Ethical Context and Ethical Leadership. [PDF]
Paralta R, Simões E, Duarte AP.
europepmc +1 more source
Low Incidence of Relapses After Vaccination in Anti‐Aquaporin‐4 Antibody‐Positive NMOSD
ABSTRACT Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%–10.6 ...
Sean J. Pittock +4 more
wiley +1 more source
From ethics to ecology: How ethical leadership drives environmental performance through green organizational identity and culture. [PDF]
Rihal J +3 more
europepmc +1 more source
Reducing Healthcare Employees' Burnout through Ethical Leadership: The Role of Altruism and Motivation. [PDF]
Wu Y +6 more
europepmc +1 more source
The Corporate Ethical Virtues Model, which is a model for measuring the ethical culture of organizations, has not been tested on its predictive validity. This study tests the relationship between this model and observed unethical behavior in work groups.
Kaptein, S.P.
core
ABSTRACT Objective To explore how cerebral hypoxia and Normal‐Appearing White Matter (NAWM) integrity affect MS lesion burden and clinical course. Methods Seventy‐nine MS patients, including 13 clinically isolated syndrome (CIS) patients and 66 relapsing–remitting multiple sclerosis (RRMS) patients, and 44 healthy controls (HCs) were recruited from ...
Xinli Wang +8 more
wiley +1 more source
Uncivil customers and work-family spillover: examining the buffering role of ethical leadership. [PDF]
Jeong J, Lee JH, Karahroodi HH, Jeong I.
europepmc +1 more source
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Ethical leadership and nurses' job performance: the mediating role of self-compassion. [PDF]
Liu X +5 more
europepmc +1 more source

